IO Biotech.jpg
IO Biotech to Present at 44th Annual Cowen Health Care Conference
February 26, 2024 16:05 ET | IO Biotech
IO Biotech to Present at 44th Annual Cowen Health Care Conference
IO Biotech.jpg
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
December 21, 2023 08:30 ET | IO Biotech
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
IO Biotech.jpg
IO Biotech Announces 2023 Third Quarter Results
November 13, 2023 08:12 ET | IO Biotech
IO Biotech Announces 2023 Third Quarter Results
IO Biotech.jpg
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
November 13, 2023 08:00 ET | IO Biotech
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
IO Biotech.jpg
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
November 10, 2023 08:00 ET | IO Biotech
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
IO Biotech.jpg
IO Biotech Announces Participation in Upcoming Investor Conferences
November 08, 2023 16:30 ET | IO Biotech
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech.jpg
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 01, 2023 08:30 ET | IO Biotech
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
IO Biotech.jpg
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
October 23, 2023 01:00 ET | IO Biotech
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced...
IO Biotech.jpg
IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 03, 2023 16:30 ET | IO Biotech
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech.jpg
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
September 12, 2023 08:05 ET | IO Biotech
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancer NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO...